QUBT's Fab 2 Plans Add Manufacturing Optionality, But Negative Gross Margins and Unproven Organic Demand Keep Us on the Sidelines

What happened

Quantum Computing Inc. announced that its planned Fab 2 facility will add semiconductor, nanophotonics, and advanced packaging capabilities intended to accelerate commercialization of quantum and photonics products. This news is consistent with management's earlier disclosure of initiating Fab 2 planning, but it remains a capital-intensive promise rather than a near-term driver of reported results. The latest 10-Q shows Q1 2026 revenue of $3.691 million was almost entirely acquisition-driven ($3.5 million from Luminar Semiconductor), while consolidated gross margin was -20% and operating expenses totaled $19.8 million, leaving no operating proof of scalable unit economics. The company's $1.41 billion in cash and investments provides a massive cushion, but that liquidity also raises the bar for capital allocation discipline; spending on Fab 2 without first demonstrating utilization-driven margin recovery would be value-destructive. Until QUBT shows organic revenue above $1 million sequentially and gross margin above 0%, the Fab 2 narrative is a future option, not a current investment case.

Implication

The Fab 2 expansion adds medium-term manufacturing capacity, but it does not change the immediate operating picture: revenue is dominated by a declining acquired business, gross margin is deeply negative, and the only auditable organic catalyst (five NeuraWave systems due in 2026) is still not delivered. At $10.50, QUBT trades near its cash-backed floor, which limits downside but also caps upside absent fundamental progress; the stock remains a high-beta quantum momentum play rather than a self-funding commercial story. We maintain a WAIT rating and would only become constructive if next quarter shows organic revenue up more than $1 million, gross margin above 0%, and on-time NeuraWave deliveries. Conversely, sequential revenue declines, continued negative gross margins, or delays in Fab 2 execution would reinforce the bear case and justify trimming above $15. Given the current uncertainty and lack of operating proof, the Fab 2 announcement alone does not alter our base-case implied value of $11.

Thesis delta

The announcement of Fab 2 adds semiconductor, nanophotonics, and packaging capabilities, but does not change the core thesis: QUBT must convert acquired revenue into improving gross margin and deliver auditable organic orders. The plan increases capital intensity and execution risk, and without near-term operating proof, the WAIT rating remains appropriate. No upward or downward revision is warranted at this time.